PF-06671008 Dose Escalation Study in Advanced Solid Tumors

Stopped early · Phase 1

Conditions studied: Neoplasms

In brief

The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06671008 in patients with advanced solid tumors with the potential to have P-cadherin expression. The study will then expand to look at the selected dose in patients with P-cadherin expressing TNBC, CRC or NSCLC.

Key facts

Study ID

NCT02659631

Run by

Pfizer

People needed

28

Starts

2016-04-28

Expected to finish

2019-03-29

Last updated by the study team

2020-05-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan Kettering Cancer Center - Westchester — Harrison, New York, United States
• Memorial Sloan Kettering Cancer Center- Clinical Trials Office — New York, New York, United States
• Memorial Sloan Kettering Cancer Center Rockefeller Outpatient Pavillion — New York, New York, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• University Hospitals Cleveland Medical Center — Cleveland, Ohio, United States
• The University of Texas - M.D. Anderson Cancer Center — Houston, Texas, United States
• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• Huntsman Cancer Hospital — Salt Lake City, Utah, United States
• Huntsman Cancer Institute — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.